Skip to Main Content
Contribute Try STAT+ Today

The Food and Drug Administration on Wednesday rejected a one-time gene therapy for hemophilia A, delaying what would have been a major medical milestone in a decision that upended the expectations of doctors, patients, and Wall Street.

The FDA’s move means the gene therapy, which promised to revolutionize the treatment of the bleeding disorder, will be delayed until at least 2022, according to BioMarin, the treatment’s manufacturer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I don’t understand this decision at all. Since when does the durability of a medication impact whether it is approved? This is a vast improvement over what it currently available, and can be fine-tuned as time goes on. I am appalled at what is going on these days at the FDA – their decisions are perplexing and disturbing. I hope they will reconsider.

  • As a retired physician I am very surprised and disappointed by the FDA decision. It would not take much factor V111 improvement to let hemophiliacs have a much better quality of life. I hope this heartless decision can be overturned!!

  • It doesn’t take much factor VIII to prevent bleeding. Those hemophiliacs who bleed enough to require the 300,000 dollars a year infusions of recombinant factor VIII tend to natively have less than 1 percent (of average normal) factor VIII. If they have as much as 5 percent, they tend not to bleed. Keeping the level above 10 percent would almost certainly prevent them from bleeding at all. Good luck to BioMarin. If this gene therapy works it would be a God Send to a lot of people. These bad hemophiliacs require iv infusion three times a week, 52 weeks a year. The cost may be as high as 500,000 dollars a year and they still get joint bleeds from time to time. Think of the difference the gene therapy could make in their quality of life.

Comments are closed.